Home > > North America And Global Rare Disease Treatment Market- Size, Share, Growth Rate, and Forecast
TABLE OF CONTENTS CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: NORTH AMERICA RARE DISEASE TREATMENT MARKET 3.1. OVERVIEW 3.2. NORTH AMERICA 3.2.1. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.2. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.3. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.4. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.2.5. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY COUNTRY 3.2.5.1. U.S. 3.2.5.1.1. U.S. RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.5.1.2. U.S. RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.5.1.3. U.S. RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.5.1.4. U.S. RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.2.5.2. CANADA 3.2.5.2.1. CANADA RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.5.2.2. CANADA RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.5.2.3. CANADA RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.5.2.4. CANADA RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.2.5.3. MEXICO 3.2.5.3.1. MEXICO RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.5.3.2. MEXICO RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.5.3.3. MEXICO RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.5.3.4. MEXICO RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.3. EUROPE CHAPTER 4: GLOBAL RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 4.1. OVERVIEW 4.2. BIOLOGICS 4.2.1. BIOLOGICS MARKET, BY REGION 4.2.1.1. NORTH AMERICA BIOLOGICS MARKET, BY COUNTRY 4.2.1.2. EUROPE BIOLOGICS MARKET, BY COUNTRY 4.2.1.3. ASIA BIOLOGICS MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA BIOLOGICS MARKET, BY COUNTRY 4.3. NON-BIOLOGICS 4.3.1. NON-BIOLOGICS MARKET, BY REGION 4.3.1.1. NORTH AMERICA NON-BIOLOGICS MARKET, BY COUNTRY 4.3.1.2. EUROPE NON-BIOLOGICS MARKET, BY COUNTRY 4.3.1.3. ASIA NON-BIOLOGICS MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA NON-BIOLOGICS MARKET, BY COUNTRY CHAPTER 5: GLOBAL RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 5.1. OVERVIEW 5.2. CANCER 5.2.1. CANCER MARKET, BY REGION 5.2.1.1. NORTH AMERICA CANCER MARKET, BY COUNTRY 5.2.1.2. EUROPE CANCER MARKET, BY COUNTRY 5.2.1.3. ASIA CANCER MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA CANCER MARKET, BY COUNTRY 5.3. BLOOD-RELATED DISORDERS 5.3.1. BLOOD-RELATED DISORDERS MARKET, BY REGION 5.3.1.1. NORTH AMERICA BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.3.1.2. EUROPE BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.3.1.3. ASIA BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.4. CENTRAL NERVOUS SYSTEM (CNS) 5.4.1. CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY REGION 5.4.1.1. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.4.1.2. EUROPE CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.4.1.3. ASIA CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.4.1.4. MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.5. RESPIRATORY DISORDERS 5.5.1. RESPIRATORY DISORDERS MARKET, BY REGION 5.5.1.1. NORTH AMERICA RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.5.1.2. EUROPE RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.5.1.3. ASIA RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.5.1.4. MIDDLE EAST & AFRICA RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.6. MUSCULOSKELETAL DISORDERS 5.6.1. MUSCULOSKELETAL DISORDERS MARKET, BY REGION 5.6.1.1. NORTH AMERICA MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.6.1.2. EUROPE MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.6.1.3. ASIA MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.6.1.4. MIDDLE EAST & AFRICA MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.7. CARDIOVASCULAR DISORDERS 5.7.1. CARDIOVASCULAR DISORDERS MARKET, BY REGION 5.7.1.1. NORTH AMERICA CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.7.1.2. EUROPE CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.7.1.3. ASIA CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.7.1.4. MIDDLE EAST & AFRICA CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.8. OTHER THERAPEUTIC AREAS 5.8.1. OTHER THERAPEUTIC AREAS MARKET, BY REGION 5.8.1.1. NORTH AMERICA OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY 5.8.1.2. EUROPE OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY 5.8.1.3. ASIA OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY 5.8.1.4. MIDDLE EAST & AFRICA OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY CHAPTER 6: GLOBAL RARE DISEASE TREATMENT MARKET, BY PATIENT 6.1. OVERVIEW 6.2. ADULT 6.2.1. ADULT MARKET, BY REGION 6.2.1.1. NORTH AMERICA ADULT MARKET, BY COUNTRY 6.2.1.2. EUROPE ADULT MARKET, BY COUNTRY 6.2.1.3. ASIA ADULT MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA ADULT MARKET, BY COUNTRY 6.3. PEDIATRIC 6.3.1. PEDIATRIC MARKET, BY REGION 6.3.1.1. NORTH AMERICA PEDIATRIC MARKET, BY COUNTRY 6.3.1.2. EUROPE PEDIATRIC MARKET, BY COUNTRY 6.3.1.3. ASIA PEDIATRIC MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA PEDIATRIC MARKET, BY COUNTRY CHAPTER 7: GLOBAL RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 7.1. OVERVIEW 7.2. ORAL 7.2.1. ORAL MARKET, BY REGION 7.2.1.1. NORTH AMERICA ORAL MARKET, BY COUNTRY 7.2.1.2. EUROPE ORAL MARKET, BY COUNTRY 7.2.1.3. ASIA ORAL MARKET, BY COUNTRY 7.2.1.4. MIDDLE EAST & AFRICA ORAL MARKET, BY COUNTRY 7.3. INJECTABLE 7.3.1. INJECTABLE MARKET, BY REGION 7.3.1.1. NORTH AMERICA INJECTABLE MARKET, BY COUNTRY 7.3.1.2. EUROPE INJECTABLE MARKET, BY COUNTRY 7.3.1.3. ASIA INJECTABLE MARKET, BY COUNTRY 7.3.1.4. MIDDLE EAST & AFRICA INJECTABLE MARKET, BY COUNTRY TABLE 92. MIDDLE EAST & AFRICA INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF TABLES TABLE 01. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 02. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 03. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 04. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 05. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 07. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($MILLION) TABLE 08. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($MILLION) TABLE 09. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($MILLION) TABLE 10. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($MILLION) TABLE 11. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 12. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 13. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 14. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 15. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 16. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 17. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 18. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 19. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 20. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 21. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 22. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 23. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 24. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 25. BIOLOGICS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 26. NORTH AMERICA BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 27. EUROPE BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 28. ASIA BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 29. MIDDLE EAST & AFRICA BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 30. NON-BIOLOGICS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 31. NORTH AMERICA NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. EUROPE NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. ASIA NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. MIDDLE EAST & AFRICA NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 35. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 36. CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 37. NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 40. MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 41. BLOOD-RELATED DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 42. NORTH AMERICA BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. EUROPE BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. ASIA BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. MIDDLE EAST & AFRICA BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 46. CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 47. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. EUROPE CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. ASIA CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 51. RESPIRATORY DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 52. NORTH AMERICA RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. EUROPE RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. ASIA RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. MIDDLE EAST & AFRICA RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 56. MUSCULOSKELETAL DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 57. NORTH AMERICA MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. EUROPE MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. ASIA MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. MIDDLE EAST & AFRICA MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 61. CARDIOVASCULAR DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 62. NORTH AMERICA CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. EUROPE CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. ASIA CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. MIDDLE EAST & AFRICA CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 66. OTHER THERAPEUTIC AREAS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 67. NORTH AMERICA OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. EUROPE OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. ASIA OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. MIDDLE EAST & AFRICA OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 72. ADULT MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 73. NORTH AMERICA ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. EUROPE ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. ASIA ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 76. MIDDLE EAST & AFRICA ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 77. PEDIATRIC MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 78. NORTH AMERICA PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 79. EUROPE PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 80. ASIA PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 81. MIDDLE EAST & AFRICA PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 82. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 83. ORAL MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 84. NORTH AMERICA ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 85. EUROPE ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 86. ASIA ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 87. MIDDLE EAST & AFRICA ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 88. INJECTABLE MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 89. NORTH AMERICA INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 90. EUROPE INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 91. ASIA INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 92. MIDDLE EAST & AFRICA INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF FIGURES CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: NORTH AMERICA RARE DISEASE TREATMENT MARKET 3.1. OVERVIEW 3.2. NORTH AMERICA 3.2.1. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.2. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.3. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.4. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.2.5. NORTH AMERICA RARE DISEASE TREATMENT MARKET, BY COUNTRY 3.2.5.1. U.S. 3.2.5.1.1. U.S. RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.5.1.2. U.S. RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.5.1.3. U.S. RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.5.1.4. U.S. RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.2.5.2. CANADA 3.2.5.2.1. CANADA RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.5.2.2. CANADA RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.5.2.3. CANADA RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.5.2.4. CANADA RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.2.5.3. MEXICO 3.2.5.3.1. MEXICO RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 3.2.5.3.2. MEXICO RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 3.2.5.3.3. MEXICO RARE DISEASE TREATMENT MARKET, BY PATIENT 3.2.5.3.4. MEXICO RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 3.3. EUROPE CHAPTER 4: GLOBAL RARE DISEASE TREATMENT MARKET, BY DRUG TYPE 4.1. OVERVIEW 4.2. BIOLOGICS 4.2.1. BIOLOGICS MARKET, BY REGION 4.2.1.1. NORTH AMERICA BIOLOGICS MARKET, BY COUNTRY 4.2.1.2. EUROPE BIOLOGICS MARKET, BY COUNTRY 4.2.1.3. ASIA BIOLOGICS MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA BIOLOGICS MARKET, BY COUNTRY 4.3. NON-BIOLOGICS 4.3.1. NON-BIOLOGICS MARKET, BY REGION 4.3.1.1. NORTH AMERICA NON-BIOLOGICS MARKET, BY COUNTRY 4.3.1.2. EUROPE NON-BIOLOGICS MARKET, BY COUNTRY 4.3.1.3. ASIA NON-BIOLOGICS MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA NON-BIOLOGICS MARKET, BY COUNTRY CHAPTER 5: GLOBAL RARE DISEASE TREATMENT MARKET, BY THERAPEUTIC AREA 5.1. OVERVIEW 5.2. CANCER 5.2.1. CANCER MARKET, BY REGION 5.2.1.1. NORTH AMERICA CANCER MARKET, BY COUNTRY 5.2.1.2. EUROPE CANCER MARKET, BY COUNTRY 5.2.1.3. ASIA CANCER MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA CANCER MARKET, BY COUNTRY 5.3. BLOOD-RELATED DISORDERS 5.3.1. BLOOD-RELATED DISORDERS MARKET, BY REGION 5.3.1.1. NORTH AMERICA BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.3.1.2. EUROPE BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.3.1.3. ASIA BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA BLOOD-RELATED DISORDERS MARKET, BY COUNTRY 5.4. CENTRAL NERVOUS SYSTEM (CNS) 5.4.1. CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY REGION 5.4.1.1. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.4.1.2. EUROPE CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.4.1.3. ASIA CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.4.1.4. MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM (CNS) MARKET, BY COUNTRY 5.5. RESPIRATORY DISORDERS 5.5.1. RESPIRATORY DISORDERS MARKET, BY REGION 5.5.1.1. NORTH AMERICA RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.5.1.2. EUROPE RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.5.1.3. ASIA RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.5.1.4. MIDDLE EAST & AFRICA RESPIRATORY DISORDERS MARKET, BY COUNTRY 5.6. MUSCULOSKELETAL DISORDERS 5.6.1. MUSCULOSKELETAL DISORDERS MARKET, BY REGION 5.6.1.1. NORTH AMERICA MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.6.1.2. EUROPE MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.6.1.3. ASIA MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.6.1.4. MIDDLE EAST & AFRICA MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY 5.7. CARDIOVASCULAR DISORDERS 5.7.1. CARDIOVASCULAR DISORDERS MARKET, BY REGION 5.7.1.1. NORTH AMERICA CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.7.1.2. EUROPE CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.7.1.3. ASIA CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.7.1.4. MIDDLE EAST & AFRICA CARDIOVASCULAR DISORDERS MARKET, BY COUNTRY 5.8. OTHER THERAPEUTIC AREAS 5.8.1. OTHER THERAPEUTIC AREAS MARKET, BY REGION 5.8.1.1. NORTH AMERICA OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY 5.8.1.2. EUROPE OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY 5.8.1.3. ASIA OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY 5.8.1.4. MIDDLE EAST & AFRICA OTHER THERAPEUTIC AREAS MARKET, BY COUNTRY CHAPTER 6: GLOBAL RARE DISEASE TREATMENT MARKET, BY PATIENT 6.1. OVERVIEW 6.2. ADULT 6.2.1. ADULT MARKET, BY REGION 6.2.1.1. NORTH AMERICA ADULT MARKET, BY COUNTRY 6.2.1.2. EUROPE ADULT MARKET, BY COUNTRY 6.2.1.3. ASIA ADULT MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA ADULT MARKET, BY COUNTRY 6.3. PEDIATRIC 6.3.1. PEDIATRIC MARKET, BY REGION 6.3.1.1. NORTH AMERICA PEDIATRIC MARKET, BY COUNTRY 6.3.1.2. EUROPE PEDIATRIC MARKET, BY COUNTRY 6.3.1.3. ASIA PEDIATRIC MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA PEDIATRIC MARKET, BY COUNTRY CHAPTER 7: GLOBAL RARE DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 7.1. OVERVIEW 7.2. ORAL 7.2.1. ORAL MARKET, BY REGION 7.2.1.1. NORTH AMERICA ORAL MARKET, BY COUNTRY 7.2.1.2. EUROPE ORAL MARKET, BY COUNTRY 7.2.1.3. ASIA ORAL MARKET, BY COUNTRY 7.2.1.4. MIDDLE EAST & AFRICA ORAL MARKET, BY COUNTRY 7.3. INJECTABLE 7.3.1. INJECTABLE MARKET, BY REGION 7.3.1.1. NORTH AMERICA INJECTABLE MARKET, BY COUNTRY 7.3.1.2. EUROPE INJECTABLE MARKET, BY COUNTRY 7.3.1.3. ASIA INJECTABLE MARKET, BY COUNTRY 7.3.1.4. MIDDLE EAST & AFRICA INJECTABLE MARKET, BY COUNTRY TABLE 01. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 02. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 03. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 04. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 05. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 07. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($MILLION) TABLE 08. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($MILLION) TABLE 09. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($MILLION) TABLE 10. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($MILLION) TABLE 11. NORTH AMERICA RARE DISEASE TREATMENT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 12. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 13. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 14. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 15. U.S. RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 16. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 17. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 18. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 19. CANADA RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 20. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 21. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 22. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 23. MEXICO RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 24. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY DRUG TYPE, 2023-2030, ($ MILLION) TABLE 25. BIOLOGICS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 26. NORTH AMERICA BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 27. EUROPE BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 28. ASIA BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 29. MIDDLE EAST & AFRICA BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 30. NON-BIOLOGICS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 31. NORTH AMERICA NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. EUROPE NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. ASIA NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. MIDDLE EAST & AFRICA NON-BIOLOGICS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 35. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY THERAPEUTIC AREA, 2023-2030, ($ MILLION) TABLE 36. CANCER MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 37. NORTH AMERICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. EUROPE CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. ASIA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 40. MIDDLE EAST & AFRICA CANCER MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 41. BLOOD-RELATED DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 42. NORTH AMERICA BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. EUROPE BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. ASIA BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. MIDDLE EAST & AFRICA BLOOD-RELATED DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 46. CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 47. NORTH AMERICA CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. EUROPE CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. ASIA CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM (CNS) MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 51. RESPIRATORY DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 52. NORTH AMERICA RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. EUROPE RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. ASIA RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. MIDDLE EAST & AFRICA RESPIRATORY DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 56. MUSCULOSKELETAL DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 57. NORTH AMERICA MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. EUROPE MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. ASIA MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. MIDDLE EAST & AFRICA MUSCULOSKELETAL DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 61. CARDIOVASCULAR DISORDERS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 62. NORTH AMERICA CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. EUROPE CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. ASIA CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. MIDDLE EAST & AFRICA CARDIOVASCULAR DISORDERS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 66. OTHER THERAPEUTIC AREAS MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 67. NORTH AMERICA OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 68. EUROPE OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. ASIA OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. MIDDLE EAST & AFRICA OTHER THERAPEUTIC AREAS MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY PATIENT, 2023-2030, ($ MILLION) TABLE 72. ADULT MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 73. NORTH AMERICA ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. EUROPE ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. ASIA ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 76. MIDDLE EAST & AFRICA ADULT MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 77. PEDIATRIC MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 78. NORTH AMERICA PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 79. EUROPE PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 80. ASIA PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 81. MIDDLE EAST & AFRICA PEDIATRIC MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 82. GLOBAL RARE DISEASE TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 83. ORAL MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 84. NORTH AMERICA ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 85. EUROPE ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 86. ASIA ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 87. MIDDLE EAST & AFRICA ORAL MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 88. INJECTABLE MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 89. NORTH AMERICA INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 90. EUROPE INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 91. ASIA INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 92. MIDDLE EAST & AFRICA INJECTABLE MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)